Read More

BriaCell Reports 71% Central Nervous System Response Rate In Advanced Breast Cancer Patients With Central Nervous System Metastases Support Clinical Efficacy Of Bria-IMT, Alone And In Combination With An Immune Checkpoint Inhibitor

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint

BCTX

Read More

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. 

AZN